Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
FPMI's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FPMI: No Debt )
FPMI' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: No Debt

F-Score: 2
Z-Score: -96.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROA (%) -1010.94
FPMI's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FPMI: -1010.94 )
FPMI' s 10-Year ROA (%) Range
Min: -900   Max: -91.93
Current: -1010.94

-900
-91.93
ROC (Joel Greenblatt) (%) -14537.50
FPMI's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FPMI: -14537.50 )
FPMI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12462.86   Max: -466.67
Current: -14537.5

-12462.86
-466.67
EBITDA Growth (%) 48.70
FPMI's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FPMI: 48.70 )
FPMI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 91.3
Current: 48.7

0
91.3
EPS Growth (%) 55.40
FPMI's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FPMI: 55.40 )
FPMI' s 10-Year EPS Growth (%) Range
Min: 0   Max: 100
Current: 55.4

0
100
» FPMI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with FPMI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -3.57
FPMI's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FPMI: -3.57 )
FPMI' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -3.57

Current Ratio 0.06
FPMI's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FPMI: 0.06 )
FPMI' s 10-Year Current Ratio Range
Min: 0.01   Max: 21.99
Current: 0.06

0.01
21.99
Quick Ratio 0.06
FPMI's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FPMI: 0.06 )
FPMI' s 10-Year Quick Ratio Range
Min: 0.01   Max: 21.99
Current: 0.06

0.01
21.99

Valuation & Return

vs
industry
vs
history

Business Description

Industry: »
Compare: » details
FluoroPharma Medical Inc., is a molecular imaging company. It is engaged in the discovery, development and commercialization of proprietary products for the positron emission tomography (PET) market.
» More Articles for FPMI

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
FluoroPharma Medical Announces Acceptance of Abstract From Phase II Clinical Trial of CardioPET (18F... Sep 02 2014
FLUOROPHARMA MEDICAL, INC. Financials Aug 23 2014
FPMI: Positive CardioPET Data. Q2 Results Aug 20 2014
FLUOROPHARMA MEDICAL, INC. Files SEC form 10-Q, Quarterly Report Aug 14 2014
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Jul 25 2014
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jul 01 2014
Eagle Pharmaceuticals (EGRX) in Focus: Stock Moves 5.6% Higher Jul 01 2014
FPMI: Additional Phase II Data Supports Utility of CardioPET Jun 11 2014
FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was... Jun 11 2014
FluoroPharma Medical Announces Presentation of Data From Phase II Clinical Trial of 18F FCPHA... May 29 2014
FluoroPharma Medical Chairman & CEO to Present at 15th Annual B. Riley Conference on May 19th at... May 19 2014
FPMI: Industry Expert Added to Already Impressive Advisory Board May 16 2014
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 16 2014
FLUOROPHARMA MEDICAL, INC. Files SEC form 10-Q, Quarterly Report May 15 2014
FluoroPharma Appoints Dr. H. William Strauss, Internationally Recognized Expert in the Field of... Apr 14 2014
FluoroPharma CEO Thijs Spoor to Be Interviewed Live Today on Clear Channel Business Talk Radio Apr 02 2014
FLUOROPHARMA MEDICAL, INC. Files SEC form 10-K, Annual Report Mar 25 2014
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Mar 14 2014
FluoroPharma Announces Appointment of Andrew H. Sassine to the Board of Directors Mar 11 2014
FPMI: Promising Phase II Data Reinforces Our Confidence in CardioPET Feb 07 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK